180
Participants
Start Date
November 19, 2019
Primary Completion Date
April 30, 2022
Study Completion Date
November 30, 2022
RV001V
RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
Placebo
Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
Rigshospitalet, Copenhagen Prostate Cancer Center, Copenhagen
Herlev & Gentofte Hospital, Department of Urology, Herlev
Odense University Hospital, Deparment of Urology, Odense
Aarhus University Hospital, Department of Urology, Aarhus
Aalborg University, Departmen of Urology, Aalborg
Icahn School of Medicine at Mount Sinai Hospitals, New York
Chesapeake Urology Research Associates, Towson
Carolina Urologic Research Center, Myrtle Beach
Tampa Bay Medical Research, Clearwater
GU Research Network/Urology Cancer Center, Omaha
The Urology Place, San Antonio
Comprehensive Cancer Centers of Nevada, Las Vegas
Gent University Hospital, Ghent
CHU de Liège, Liège
Hôpital Erasme, Liège
Urinvejskirurgisk afdeling, Hospitalsenheden Vest, Holstebro
Meilahti Tower Hospital, Helsinki
Oulu University Hospital, Oulu
Seinajoki Central Hospital, Seinäjoki
Tampere University Hospital, Tampere
Turku University Hospital, Turku
University Hospital Dresden, Dresden
Urologicum Duisburg, Duisburg
Urologische Praxis Dr. Wolfgang Warnack, Hagenow
Urologische Praxis. M. Markov, Halle
Studienpraxis Urologie, Nürtingen
University Hospital Tuebingen, Tübingen
Sahlgrenska University Hospital, Gothenburg
Skåne University Hospital, Malmo
Örebro University Hospital, Örebro
Karolinska University Hospital, Stockholm
Umeå University Hospital, Umeå
Clatterbridge Centre for Oncology, Liverpool
Royal Free London NHS Foundation Trust Royal Free Hospital, London
Nottingham University Hospital, Nottingham
University Hospital Southampton, Southampton
RhoVac APS
INDUSTRY